978P Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Year: 2023
Type: article
Study design: Observational Study
Source: Annals of Oncology
Institutions: Imperial College London, Taipei Veterans General Hospital, University of Kansas Medical Center, IRCCS Humanitas Research Hospital, University Medical Center Hamburg-Eppendorf, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, The University of Texas MD Anderson Cancer Center, Medizinische Hochschule Hannover, University of Freiburg, University Medical Center Freiburg, Campus Bio Medico University Hospital, Kindai University, University of Pisa, Azienda Ospedaliera Universitaria Pisana, Medical University of Vienna, OU Health Stephenson Cancer Center, University of Oklahoma, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, China Medical University, Azienda Ospedaliero-Universitaria delle Marche, CHA University Bundang Medical Center, Hammersmith Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4387811249